Comparing Two Dual Blood Pressure Treatments After Coronary Artery Stenting in Adults Aged 50 to 70

What this Trial Is About

Researchers are comparing two different dual antihypertensive treatment plans in people aged 50 to 70 who have arterial hypertension and coronary artery disease after undergoing elective percutaneous coronary intervention PCI with coronary artery stenting. The goal is to assess which combination better controls blood pressure and improves symptoms and quality of life. This is a randomized, open-label study initiated by researchers to evaluate these therapies in this patient group. Participants will be randomly assigned to receive either an angiotensin receptor blocker combined with a thiazide diuretic Losartan Hydrochlorothiazide or an angiotensin receptor blocker combined with a dihydropyridine calcium channel blocker Amlodipine Azilsartan. These dual therapies are given after PCI and coronary artery stenting during the current hospitalization. The study treatments are administered as part of their post-procedure care. During the study, participants will be monitored at hospital discharge and followed up through telemedicine visits at 2 weeks, 4 weeks, and 12 weeks after discharge. Researchers will measure changes in systolic and diastolic blood pressure, angina symptoms using the Seattle Angina Questionnaire, physical limitations, need for additional medical care, and overall patient satisfaction. The total follow-up period lasts up to 12 weeks after discharge.

Comparative Effectiveness of Dual Antihypertensive Regimens in Patients After Percutaneous Coronary Intervention